Presentation and outcome of twenty patients with synchronous stage IV rectal carcinoma
Purpose: Palliative treatment techniques for advanced stage rectal cancer should be designed according to the patients’ major symptoms. Combined chemo-radiation therapy is effective choice for symptomatic patients with good performance status. In this study, we reviewed our patients' stage IV rectal carcinoma in regard to most common presentation, outcome and possible prognostic features.
Methods Medical chart of twenty patients who were diagnosed with stage IV rectal carcinoma, were reviewed based on the hospital database information, which included images, radiotherapy charts, and their follow up notes.
Results: All patients were young with age less than 40 years. Bleeding per rectum, pain, and symptoms of obstruction were the most common presentation. Seven patients had solitary lesion and 13 patients had multiple lesions. Eleven patients with multiple metastases were treated with palliative chemotherapy and radiotherapy. Patients who had solitary metastases to liver had a median survival time of 49 months versus 13.5 months for other patients (p = 0.001).
Conclusion: Patients who presented with solitary liver metastases could be treated with a course of neoadjuvant chemo-radiotherapy similar to the curative one.
Cite this article as: Aboziada MA, Attia AM, Alhamad AA. Presentation and outcome of twenty patients with synchronous stage IV rectal carcinoma. Int J Cancer Ther Oncol 2014; 2(3):020313. DOI:10.14319/ijcto.0203.13
Surveillance, Epidemiology and End Results Program (www.seer.cancer.gov) SEER* Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
Edge, SB, Byrd, DR, Compton, CC, et al (Eds). AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, New York: Springer; 2010, p.143.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
Rothenberger DA. Palliative therapy of rectal cancer. Overview: epidemiology, indications, goals, extent, and nature of work-up. J Gastrointest Surg 2004; 8: 259-61.
Ronnekleiv-Kelly SM, Kennedy GD. Management of stage Ⅳ rectal cancer: Palliative options. World J Gastroenterol 2011; 17: 835-47.
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
Rosen SA, Buell JF, Yoshida A, Kazsuba S, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg 2000; 135:530-5.
Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004; 22:3475-84.
Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of Surveillance, Epidemiology, and End Results data, 1988 to 2000. Ann Surg Oncol 2005; 12:637-45.
Eisenberger A, Whelan RL, Neugut AI. Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis 2008; 23:559-68.
Tebbutt NC, Norman AR, Cunningham D, Hill ME, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52:568-73.
Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann SurgOncol 1999; 6:651-7.
Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27:3379-84.
Sarela AI, Guthrie JA, Seymour MT, et al. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001; 88:1352-6.
Hatfield P, Sebag-Montefiore D. The use of radiotherapy in rectal cancer. Scand J Surg 2003; 92: 65–73.
Saltz LB. Palliative management of rectal cancer: The roles of chemotherapy and radiation therapy. J Gastrointest Surg 2004; 8: 274-6.
Scheithauer W, Rosen H, Kornek GV, et al. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752-5.
Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321:531-5.
Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26:5721-7.
Renouf DJ, Lim HJ, Speers C, et al. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer 2011; 10:97-101.
Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J SurgOncol 2005; 89: 211-7.
Scoggins CR, Meszoely IM, Blanke CD, et al. Non operative Management of Primary Colorectal Cancer in Patients with Stage IV Disease. Ann Surg Oncol 1999; 6: 651-7.
Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13:668-76.
Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94:982-99.
Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247:125-35.
Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97:1110-8.
Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 2009; 115:752-9.
Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007; 109:718-26.
Arbea L, Ramos LI, Martínez-Monge R, et al. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol 2010; 5:17.
Teoh M, Clark CH, Wood K, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 2011; 84:967-96.
Rana S. Clinical dosimetric impact of Acuros XB and analytical anisotropic algorithm (AAA) on real lung cancer treatment plans: review. Int J Cancer Ther Oncol 2014; 2:02019.
Lu L. Dose calculation algorithms in external beam photon radiation therapy. Int J Cancer Ther Oncol 2013; 1:01025.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.